Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 247

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 247
---
ation in consideration of the contribution
of their equity ownership in LipoVation.

On December 31, 2024, the Company issued 2,800,000
shares of its Common Stock to the Chief Operating Officer upon her exercise of stock options.

These transactions were exempt from registration
under Section 4(a)(2) and/or Rule 506(b) of Regulation D and/or Regulation S as promulgated by the Securities and Exchange Commission
under the Securities Act, as transactions by an issuer not involving any public offering. None of the securities were sold through an
underwriter and, accordingly, there were no underwriting discounts or commissions involved.

ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Item 16. Exhibits and Financial Statement Schedules.

(a) Exhibits: Reference is made
to the Exhibit Index following the signature pages hereto, which Exhibit Index is hereby incorporated into this Item.

(b) Financial Statement Schedules:
All schedules are omitted because the required information is inapplicable, or the information is presented in the financial statements
and the related notes.

ITEM 17. UNDERTAKINGS

| (a) | The undersigned registrant 
 hereby undertakes:         |

| (1) | To file, during                                                                                                
 any period in which offers or sales are being made, a post-effective amendment to this registration statement: |                                                                                                                                          |
|     | -i                                                                                                             | To include any prospectus                                                                                                                
 required by section 10(a)(3) of the Securities Act of 1933;                                                                              |
|     | -ii                                                                                                            | To reflect in the prospectus                                                                                                             
 any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) 
 which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.      
 Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities         
 offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering         
 range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes     
 in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation              
 of Registration Fee” table in the effective registration statement.                                                                      |

<div align='center'>II